Alexion Pharmaceuticals, Inc. (ALXN) submitted on Tuesday a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of ALXN1210, the Company's investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
from RTT - Biotech https://ift.tt/2I1IG7V
via IFTTT
No comments:
Post a Comment